Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Walgren

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Blood|March 21, 2009
Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibilityJeffrey A Knight, Andrew D Skol, Abhijit Shinde, et al.
Current Medical Research and Opinion|July 7, 2021
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE studyHiroya Taniguchi, Takayuki Yoshino, Kensei Yamaguchi, et al.
Blood|February 16, 2023
Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitorEliana B Gomez, Kevin Ebata, Hetal S Randeria, et al.
British Journal of Clinical Pharmacology|January 14, 2022
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapyRonald de Wit, Thomas Powles, Daniel Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II TrialDaniel P Petrylak, Scott T Tagawa, Manish Kohli, et al.
Oncotarget|March 24, 2018
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumorsBruce W Konicek, Andrew R Capen, Kelly M Credille, et al.
Investigational New Drugs|January 1, 2013
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsS Betty Yan, Victoria L Peek, Rose Ajamie, et al.
Blood Cancer Journal|April 16, 2013
Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617FL Ma, J R Clayton, R A Walgren, et al.
The Lancet. Oncology|September 30, 2021
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 studyJuan W Valle, Arndt Vogel, Crystal S Denlinger, et al.
Haematologica|October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialNirav N Shah, Michael Wang, Lindsey E Roeker, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Blood|March 21, 2009
Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibilityJeffrey A Knight, Andrew D Skol, Abhijit Shinde, et al.
Current Medical Research and Opinion|July 7, 2021
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE studyHiroya Taniguchi, Takayuki Yoshino, Kensei Yamaguchi, et al.
Blood|February 16, 2023
Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitorEliana B Gomez, Kevin Ebata, Hetal S Randeria, et al.
British Journal of Clinical Pharmacology|January 14, 2022
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapyRonald de Wit, Thomas Powles, Daniel Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II TrialDaniel P Petrylak, Scott T Tagawa, Manish Kohli, et al.
Oncotarget|March 24, 2018
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumorsBruce W Konicek, Andrew R Capen, Kelly M Credille, et al.
Investigational New Drugs|January 1, 2013
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsS Betty Yan, Victoria L Peek, Rose Ajamie, et al.
Blood Cancer Journal|April 16, 2013
Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617FL Ma, J R Clayton, R A Walgren, et al.
The Lancet. Oncology|September 30, 2021
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 studyJuan W Valle, Arndt Vogel, Crystal S Denlinger, et al.
Haematologica|October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialNirav N Shah, Michael Wang, Lindsey E Roeker, et al.
Pageof 4